<乌鸦传媒 class="page_title">Clinical Essentials
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
<乌鸦传媒>
A large, well-phenotyped cohort study assessed patients with MASLD to determine if this risk group is undergoing adequate surveillance.
<乌鸦传媒 class="article_title">
Fatty Liver Disease and Heavy Alcohol Use: A Bad Combination
Korean researchers recently analyzed rates of alcohol consumption and their effect on liver-related mortality risk in roughly 1 million people who were, or were not, diagnosed with metabolic dysfunction-associated fatty liver disease.
<乌鸦传媒 class="article_title">
Lean MASH Patients Face Higher Mortality and Worse Outcomes
These data confirm that lean patients with MASH may be at greater risk of poor health outcomes than non-lean patients with MASH.
<乌鸦传媒 class="article_title">
MASLD Clinical Outcomes: Numerous, Dangerous
Data on clinical outcomes in MASLD are lacking. This study鈥檚 goal was to provide a comprehensive meta-analysis of the longitudinal outcomes associated with MASLD.
<乌鸦传媒 class="article_title">
In MASLD, Which Serum Lipid-Soluble Micronutrients Heighten Risk?
Serum lipid-soluble micronutrients, such as 25(OH)D and carotenoids, may be protective in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), whereas tocopherols may be associated with pathology, according to this report.
Investigators reported on the clinical utility of several non-invasive screening methods to reduce the burden of invasive liver tissue sampling in patients at risk of MASH.
<乌鸦传媒 class="article_title">
Assessing MASH Risk in Older Adults with Diabetes
Patients over age 50 with type 2 diabetes are at particular risk for metabolic dysfunction-associated steatohepatitis, according to the results of this study.
<乌鸦传媒 class="article_title">
MASLD in Lean Patients: What do We Know?
This systematic review of the literature provides an interpretation of the new criteria related to lean MASLD.